Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03980730 · ClinicalTrials.gov registry record · Phase 2
Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
A Phase 2 study, sponsored by vTv Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT03980730: Clinical Trial Phase 2 study, sponsored by vTv Therapeutics.
NCT03980730 is a Phase 2 study that was terminated before completion, run by vTv Therapeutics. The registered enrollment target is 43 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03980730, a Phase 2 study, was terminated before completion, sponsored by vTv Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 9 months (in Part 1) or 21 months (in Part 2).
Primary Outcome
The Alzheimer's Disease Assessment Scale - Cognitive Subscale 14 Item (ADAS-cog14) scoring range is from 0 to 90, with higher scores indicating greater cognitive impairment
Interventions
- DRUG Placebo
- DRUG Azeliragon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2019-06-27 |
| Est. Completion | 2021-01-29 |
| Phase | Phase 2 |
Why NCT03980730 stopped before completion
NCT03980730 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03980730 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03980730 about?
NCT03980730 is a clinical study titled "Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance". This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 9 months (in Part 1) or 21 months (in Part 2).
What is the current status of trial NCT03980730?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2019-06-27. Estimated completion is 2021-01-29.
What interventions are being tested in trial NCT03980730?
The interventions under investigation include: Placebo (DRUG), Azeliragon (DRUG).
Who is sponsoring clinical trial NCT03980730?
This trial is sponsored by vTv Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03980730's enrollment target sits among peer trials
43 1332nd of 2000 higher than 662 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI